Piper Sandler Maintains Overweight on Aptose Biosciences, Lowers Price Target to $37
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Aptose Biosciences (NASDAQ:APTO) but lowers the price target from $45 to $37.
June 07, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler maintains Overweight rating on Aptose Biosciences (NASDAQ:APTO) and lowers price target from $45 to $37.
The news directly mentions Aptose Biosciences (NASDAQ:APTO) and the lowered price target by Piper Sandler. While the Overweight rating is maintained, the reduced price target may have a neutral short-term impact on the stock price as it indicates a lower future valuation, but still suggests a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100